Leptomeningeal metastases from NSCLC

• Published in: Thoracic cancer 2015-07, Vol.6 (4), p.407-412
• Main Authors: Xu, Qinghua, Chen, Xiu, Qian, Danwen, Wang, Yongsheng, Meng, Shuyan, Liu, Hui, Zhou, Caicun
• Format: Article
• Language: English
• Subjects: Age; Cancer therapies; Chemotherapy; Epidermal growth factor; Gender; Histology; Lung cancer; Medical prognosis; Metastasis; Mutation; NMR; Nuclear magnetic resonance; Oncology; Patients; Radiation therapy
• ISSN: 1759-7706; 1759-7714
• DOI: 10.1111/1759-7714.12188

BackgroundLeptomeningeal metastases (LM) from non‐small cell lung cancer (NSCLC) are associated with poor prognosis and optimal treatment for this subgroup of NSCLC patients is controversial. The purpose of this study is to evaluate treatment options and prognostic factors of NSCLC patients with LM.MethodsWe retrospectively analyzed data of 108 patients who had been diagnosed with LM from NSCLC between May 2006 and August 2013.ResultsThe median survival time (MST) of the 108 patients was 5.3 months, and the one‐year survival rate was 23.7%. Forty‐nine patients received whole brain radiotherapy (WBRT) and the MST of patients who received WBRT and those who did not were 6.4 and 4.3 months, respectively. Forty‐two patients were treated with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) after being diagnosed with LM. These patients had prolonged survival (11.1 vs. 4.4 months). Patients who received concomitant WBRT and EGFR‐TKIs had the longest MST (12.3 months). Eastern Cooperative Oncology Group performance status, whether patients received WBRT, and/or EGFR‐TKIs were independent prognostic factors for patients with LM from NSCLC.ConclusionWBRT, EGFR‐TKIs or combined therapy, could lead to better clinical outcomes for NSCLC patients with LM. EGFR‐TKIs plus WBRT has the potential to be the standard strategy for LM in NSCLC patients.